http://www.pharmexec.com/pharmexec/Deals/Article/list/43875 Mergers, acquisitions, strategic partnerships, and product licensing. Plus, strategies and tactics for better deal-making 2013-05-19T15:20:50Z http://www.pharmexec.com/pharmexec/Deals/2013-Dealmakers-Outlook/ArticleStandard/Article/detail/810225?contextCategoryId=43875&ref=25 Pharm Exec's annual look at the trends and best practices in biopharm licensing and M&A for the year ahead. 2013-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/152013/810225/Dealmakers_120_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/152013/810225null XML http://www.pharmexec.com/pharmexec/Deals/Safeguarding-the-Value-of-Patent-Assets/ArticleStandard/Article/detail/808522?contextCategoryId=43875&ref=25 As small biotech firms test the water in partnerships with Big Pharma, the best calling card is a well-framed strategy on intellectual property. 2013-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/122013/808522null XML http://www.pharmexec.com/pharmexec/Deals/Transforming-Drug-Development-A-LillyndashCovance-/ArticleStandard/Article/detail/799846?contextCategoryId=43875&ref=25 Eli Lilly's pioneering pact with leading CRO Covance made big news when it happened. Four years later, both parties can point to metrics that suggest the benefit is mutual. 2012-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/502012/799846/vials_120_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Deals/2012-Dealmakers-Outlook/ArticleStandard/Article/detail/777876?contextCategoryId=43875&ref=25 Pharm Exec convened a panel of heavy hitters in business development to crack the bat on best practices in licensing and M&A for the year ahead. 2012-06-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242012/777876/dealmaker_120_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Deals/Pharm-Execs-2012-Pipeline-Report/ArticleStandard/Article/detail/752361?contextCategoryId=43875&ref=25 It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle? 2011-12-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/512011/752361/pipeline-small_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Deals/30-Years-of-Pharma-Perspective-in-Numbers-Part-3/ArticleStandard/Article/detail/744325?contextCategoryId=43875&ref=25 Top 10 Companies by Market Share 2011-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422011/744325null XML http://www.pharmexec.com/pharmexec/Deals/30-Years-of-Pharma-Perspective-in-Numbers-Part-1/ArticleStandard/Article/detail/744319?contextCategoryId=43875&ref=25 Top 10 Products Worldwide 2011-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422011/744319null XML http://www.pharmexec.com/pharmexec/Current+Issue/30-Years-of-Pharma-Perspective-in-Numbers-Part-2/ArticleStandard/Article/detail/744320?contextCategoryId=43875&ref=25 30 Years of Pharma: Perspective in Numbers 2011-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422011/744320null XML http://www.pharmexec.com/pharmexec/Deals/Pharm-Execs-10th-Annual-Industry-Audit/ArticleStandard/Article/detail/739266?contextCategoryId=43875&ref=25 Bill Trombetta surveys the landscape of pharma financials over the past year, and shows which companies rode the wave to the top of the industry in delivering value to shareholders. 2011-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372011/739266/industry-audit_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372011/739266null XML http://www.pharmexec.com/pharmexec/Deals/Seeing-the-Fire-Behind-the-Smoke/ArticleStandard/Article/detail/730208?contextCategoryId=43875&ref=25 Structuring a good deal depends on understanding your partner—and a high degree of specificity 2011-07-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282011/730208null XML http://www.pharmexec.com/pharmexec/Deals/2011-Dealmakers-Outlook/ArticleStandard/Article/detail/726081?contextCategoryId=43875&ref=25 With Yankee stadium as the backdrop, Pharm Exec convened its annual panel of eight business development experts to crack the bat on best practice in licensing and M&A for the year ahead. 2011-06-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242011/726081/Lead-Image-for-Dealmakers3_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Deals/Filling-in-the-Bigger-Picture/ArticleStandard/Article/detail/726110?contextCategoryId=43875&ref=25 Part II of The Avoca Group's 2011 CRO survey on clinical development outsourcing relationships 2011-06-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242011/726110null XML http://www.pharmexec.com/pharmexec/Deals/Teva-Snatches-Cephalon-from-Valeant/ArticleStandard/Article/detail/722098?contextCategoryId=43875&ref=25 Israel-based Teva Industries seals deal to acquire Cephalon for $6.8 billion. 2011-05-05T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/202011/722098null HTML http://www.pharmexec.com/pharmexec/Global+Report/12th-Annual-Pharm-Exec-50/ArticleStandard/Article/detail/719596?contextCategoryId=43875&ref=25 Who's taken this year's top spot? Find out in Pharm Exec's annual run-down of the world's Top 50 pharma companies. 2011-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/192011/719596/phara50-cropped_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/192011/719596/phara50_flash.jpg XML http://www.pharmexec.com/pharmexec/From+the+Editor/Keeping-Your-Place-on-the-Nifty-50/ArticleStandard/Article/detail/719591?contextCategoryId=43875&ref=25 What do the Pharm Exec 50 numbers tell us? The dominant theme seems to be one of gradual restructuring toward a post-patent-cliff era. 2011-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/192011/719591/W_Looney-for-web_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/192011/719591null XML http://www.pharmexec.com/pharmexec/Technology/White-Coats-amp-Suit-Jackets-A-Coming-of-Age-Story/ArticleStandard/Article/detail/716283?contextCategoryId=43875&ref=25 The parnership between academia and industry is evolving. Will it keep innovation at a premium? 2011-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/162011/716283null XML http://www.pharmexec.com/pharmexec/Back+Page/Tracking-the-US-Market-A-Statistical-Self-Portrait/ArticleStandard/Article/detail/707515?contextCategoryId=43875&ref=25 What are some of the essential characteristics of the US market? Statistics drawn from the 2011 Statistical Abstract of the US shed some light 2011-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072011/707515/57283738paint_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072011/707515null XML http://www.pharmexec.com/pharmexec/Deals/Integrating-RampD-Within-MampAs/ArticleStandard/Article/detail/695699?contextCategoryId=43875&ref=25 The CEO should be able to communicate the vision of a merger—strategically, financially, operationally, and with the entire organization in mind 2010-11-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/472010/695699null XML http://www.pharmexec.com/pharmexec/Deals/5-Years-Later-Conatus-Acquires-Idun/ArticleStandard/Article/detail/681404?contextCategoryId=43875&ref=25 Former Idun Pharma team buys back company from Pfizer. 2010-08-02T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322010/681404null HTML http://www.pharmexec.com/pharmexec/Deals/Dealmaking-Roundtable/ArticleStandard/Article/detail/670560?contextCategoryId=43875&ref=25 A panel of bankers and industry executives discuss what's ahead in deals for 2010. 2010-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/212010/670560null XML http://www.pharmexec.com/pharmexec/Deals/GSK-Inks-15-Billion-Collaboration-Deal-with-Isis/ArticleStandard/Article/detail/663527?contextCategoryId=43875&ref=25 Glaxo and Isis formed a billion-dollar alliance to create new RNA therapies for the rare and infectious disease segment. The key ingredient in the deal is Isis' drug discovery platform. Could it be a game changer? GSK thinks so. 2010-03-31T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/142010/663527null HTML http://www.pharmexec.com/pharmexec/Deals/Astellas-Hostile-Takeover-Turns-Even-More-Hostile/ArticleStandard/Article/detail/659855?contextCategoryId=43875&ref=25 The Japan-based company filed a lawsuit against OSI Pharmaceuticals for rejecting its tender offer, but will this strategy work? 2010-03-03T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102010/659855null HTML http://www.pharmexec.com/pharmexec/News+Analysis/Novartis-Bids-Big-on-Alcon/ArticleStandard/Article/detail/650517?contextCategoryId=43875&ref=25 It's just a few days into the new year and already a potential megamerger has been announced: Novartis offered $39 billion for complete control of ocular drug manufacturer Alcon. 2010-01-06T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/022010/650517null HTML http://www.pharmexec.com/pharmexec/Deals/Glaxo-Vies-for-a-Second-Act-in-HIV/ArticleStandard/Article/detail/639343?contextCategoryId=43875&ref=25 A novel joint venture between Glaxo and Pfizer is big on promise. But the combined portfolio and pipeline of HIV drugs? Not so much. 2009-11-04T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/452009/639343null HTML http://www.pharmexec.com/pharmexec/News+Analysis/JampJ-Slims-Down-Elan-Offer-sans-Tysabri/ArticleStandard/Article/detail/626746?contextCategoryId=43875&ref=25 Elan was forced to trim $100 million off its billion-dollar deal with J&J due to a 50/50 agreement with Biogen Idec involving co-ownership of MS drug Tysabri. Now J&J is out a major drug, Elan is out a good chunk of cash, and Biogen Idec is pondering its next move. 2009-09-16T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/382009/626746null HTML http://www.pharmexec.com/pharmexec/Deals/GSK-Signs-120M-Deal-to-Market-DMab-Overseas/ArticleStandard/Article/detail/615227?contextCategoryId=43875&ref=25 Amgen's and GSK will partner to market Amgen's blockbuster osteoporosis treatment DMab in Europe, China, and other overseas countries once it is approved. 2009-07-30T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/312009/615227null REMOTE http://www.pharmexec.com/pharmexec/Deals/GSK-Teams-with-Shenzhen-Neptunus-for-Chinese-Vacci/ArticleStandard/Article/detail/602668?contextCategoryId=43875&ref=25 GlaxoSmithKline is expanding its influenza vaccine efforts through a joint R&D alliance with Shenzhen Neptunus. The goal: to tap the world’s biggest market and attempt to deliver flu shots to more than a billion people. 2009-06-10T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/242009/602668null HTML http://www.pharmexec.com/pharmexec/Deals/GSK-Signs-Deal-with-Concert-Pharma-to-the-Tune-of-/ArticleStandard/Article/detail/601466?contextCategoryId=43875&ref=25 GlaxoSmithKline has entered into a collaboration deal with Concert to create drugs using deuterium—“heavy hydrogen”—that can be gathered from seawater and used to alter the way molecules perform in the body. 2009-06-03T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/232009/601466null HTML http://www.pharmexec.com/pharmexec/Deals/Pfizer-and-Glaxo-Join-Forces-in-HIV-Venture/ArticleStandard/Article/detail/594629?contextCategoryId=43875&ref=25 The two pharma giants announced plans to form a new specialty company focused on HIV drug development. The new, independent firm will have a total of 11 drugs on the market, with another six on the horizon, securing its place as a powerhouse in the HIV market. 2009-04-22T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/172009/594629null HTML http://www.pharmexec.com/pharmexec/Deals/GSK-Grabs-Derma-Firm-for-29-Billion/ArticleStandard/Article/detail/586391?contextCategoryId=43875&ref=25 Stiefel Labs is under new management. The dermatology company was purchased by GSK in an effort to bolster its existing skincare line. 2009-04-22T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/112009/586391null HTML http://www.pharmexec.com/pharmexec/Deals+Articles/A-Season-in-Financial-Hell/ArticleStandard/Article/detail/592060?contextCategoryId=43875&ref=25 From the depths of the Great Recession, Pharm Exec called in pros on all sides of the M&A business to help us deal. 2009-04-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/152009/592060/PE0409_financialhell_flash.jpg XML http://www.pharmexec.com/pharmexec/Deals/Gilead-Buys-CV-Therapeutics-Update-1/ArticleStandard/Article/detail/587457?contextCategoryId=43875&ref=25 The morning's other big M&A news comes out of the Bay Area biotech industry, where Gilead Sciences announced that will purchase CV Therapeutics for $1.4 billion. 2009-03-12T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/122009/587457null REMOTE http://www.pharmexec.com/pharmexec/Deals/Roche-and-Genentech-Seal-the-Deal-for-468-Billion/ArticleStandard/Article/detail/587456?contextCategoryId=43875&ref=25 After months and months of back and forth over the true value of Genentech, Roche finally got the good news it's been looking for: Genentech's board of directors, this morning, approved Roche's latest offer of $46.8 billion ($95 per share) to acquire all shares of the biotech giant. 2009-03-05T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/122009/587456null REMOTE http://www.pharmexec.com/pharmexec/News+Analysis/Merck-Takes-Unusual-Merger-Tactic-in-Schering-Deal/ArticleStandard/Article/detail/586378?contextCategoryId=43875&ref=25 The Merck acquisition of Schering-Plough may have surprised few, the approach has raised some eyebrows. Rather than buy the company outright, Merck going through a convoluted reverse merger deal to keep Schering's licensing deals secure. Was it the right move? 2009-03-04T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/112009/586378null HTML http://www.pharmexec.com/pharmexec/Deals/Astellas-to-Nominate-Two-Directors-to-CV-Therapeut/ArticleStandard/Article/detail/586380?contextCategoryId=43875&ref=25 Astellas's hostile bid takes a new turn as the Japanese company tries to oust remaining CVT board members and replace them with their own. 2009-03-03T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/112009/586380null HTML http://www.pharmexec.com/pharmexec/Deals/Genentech-and-Roche-May-Be-Close-to-Deal/ArticleStandard/Article/detail/594630?contextCategoryId=43875&ref=25 All signs point to Genentech acquisition. 2009-03-03T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/172009/594630null HTML http://www.pharmexec.com/pharmexec/Deals/Specialty-Firms-Shoot-Down-Big-Money-Bids/ArticleStandard/Article/detail/583391?contextCategoryId=43875&ref=25 CV Therapeutics and Genetech rejected offers from big-name suitors. Are they playing hard to get or are they just not that into them? 2009-02-25T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/092009/583391null HTML http://www.pharmexec.com/pharmexec/Strategy+Articles/Stream-Power/ArticleStandard/Article/detail/580043?contextCategoryId=43875&ref=25 Convert future revenue into present value with alternative approaches to access capital. 2009-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/062009/580043/PE0209_stream_flash.jpg XML http://www.pharmexec.com/pharmexec/Deals/Two-Become-One-Pfizer-Acquires-Wyeth/ArticleStandard/Article/detail/577983?contextCategoryId=43875&ref=25 Pfizer hit hard with the surprise purchase of Wyeth. But will the pharma giant strike out in the long run? Analysts ponder the long and short-term ramifications of this monster acquisition. 2009-01-28T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/052009/577983null HTML http://www.pharmexec.com/pharmexec/Deals/Astellas-Takes-Another-Stab-at-CV/ArticleStandard/Article/detail/577972?contextCategoryId=43875&ref=25 Astellas bumped its bid for CV Therapeutics to $1 billion, but analysts doubt the offer is high enough to get the biotech's board of directors to sign on the dotted line. 2009-01-28T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/052009/577972null HTML http://www.pharmexec.com/pharmexec/Deals/BMS-Tops-List-of-Patent-Approvals/ArticleStandard/Article/detail/577984?contextCategoryId=43875&ref=25 Big name patent expirations may be looming, but that's not stopping pharma companies from filing - and getting approved for - dozens of new patents. Pharm Exec looks at which companies are getting the most approvals, and how 2008 compared to previous years. 2009-01-28T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/052009/577984null HTML http://www.pharmexec.com/pharmexec/Deals/Alpharma-Approves-King-Purchase/ArticleStandard/Article/detail/568240?contextCategoryId=43875&ref=25 After months of negotiations and veiled threats, Alpharma's board of directors has sealed the deal with King Pharmaceuticals. Alpharma is now $1.6 billion richer, and King gets access to a handful of new pain treatments. 2008-11-26T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/482008/568240null HTML http://www.pharmexec.com/pharmexec/Deals/GSK-Bolsters-Alzheimers-Portfolio-with-Affiris-Dea/ArticleStandard/Article/detail/561585?contextCategoryId=43875&ref=25 Affiris struck a deal with GlaxoSmithKline to develop two Alzheimer's treatments. As part of the agreement, GSK gains a fancy protein technology that could be a boon for future molecules. 2008-10-29T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/442008/561585null HTML http://www.pharmexec.com/pharmexec/Deals/Pharma-Not-as-Fazed-by-Wall-Street-Turmoil/ArticleStandard/Article/detail/558741?contextCategoryId=43875&ref=25 Analysts report that Big Pharma isn't being hit that hard by the credit crunch due to the large amount of cash many companies have in their coffers for mergers and acquisitions. However, smaller firms looking to be sold may have a hard time holding out for higher offers. 2008-10-15T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422008/558741null HTML http://www.pharmexec.com/pharmexec/Deals/GSK-to-Work-with-Valeant-on-Epilepsy-Drug/ArticleStandard/Article/detail/547458?contextCategoryId=43875&ref=25 After a year of layoffs and restructuring, Valeant Pharma scores big with a collaboration deal worth up to $670 million. 2008-09-04T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/362008/547458null HTML http://www.pharmexec.com/pharmexec/Deals+Articles/Place-Your-Bets/ArticleStandard/Article/detail/548225?contextCategoryId=43875&ref=25 The industry is a-changing. Here are eight seminal events that describe how. 2008-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372008/548225/PE0908_placeyourbets_flash.jpg XML http://www.pharmexec.com/pharmexec/Deals/Genentech-Launches-Employee-Retention-Program/ArticleStandard/Article/detail/543113?contextCategoryId=43875&ref=25 Tacked on to Genentech's press statement about its rejection of Roche's offer, the biotech firm announced the formation of a program to address employee concerns. 2008-08-20T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/342008/543113null HTML http://www.pharmexec.com/pharmexec/Deals/BMS-Bids-on-ImClone/ArticleStandard/Article/detail/534039?contextCategoryId=43875&ref=25 Whether or not BMS's $4.5 billion offer for ImClone is fair is up in the air, but either way BMS stands to gain chunk of change if its bid is approved. 2008-08-06T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/322008/534039null HTML http://www.pharmexec.com/pharmexec/Deals/Roche-Makes-44B-Offer-for-Control-of-Genentech/ArticleStandard/Article/detail/531192?contextCategoryId=43875&ref=25 After years of owning a majority share in Genentech, Roche makes a play to buy out the rest of the biotech firm. 2008-07-23T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/302008/531192null HTML http://www.pharmexec.com/pharmexec/Deals/Heparin-Maker-Acquired-by-German-Firm/ArticleStandard/Article/detail/528640?contextCategoryId=43875&ref=25 Fresenius snagged injectible manufacturer APP Pharmaceuticals in a $3.7 billion cash deal. Along with entry into the US market, Fresenius also gets access to one of the largest suppliers of heparin. 2008-07-10T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282008/528640null HTML http://www.pharmexec.com/pharmexec/Deals/Merck-Signs-100M-Development-Deal-with-Ranbaxy/ArticleStandard/Article/detail/516650?contextCategoryId=43875&ref=25 In a win-win situation for both companies, Merck gets access to one of the hottest generics firms in the world while Ranbaxy gets a chance to hang with the big boys. 2008-05-14T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/202008/516650null HTML http://www.pharmexec.com/pharmexec/Strategy/GSK-Snags-Sirtris-for-720M/ArticleStandard/Article/detail/512998?contextCategoryId=43875&ref=25 Small biotech company is creating a buzz with a diabetes drug that incorporates a component found in red wine. Pharm Exec talks to Sirtris CEO Christoph Westphal about the merger and the battle against diseases of aging. 2008-04-30T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/182008/512998null HTML http://www.pharmexec.com/pharmexec/Deals/Takeda-Picks-Up-Millennium/ArticleStandard/Article/detail/510241?contextCategoryId=43875&ref=25 Japanese drugmaker buys the cancer-specialist biotech for a whopping $8.8 billion. 2008-04-16T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/162008/510241null HTML http://www.pharmexec.com/pharmexec/Rotating+Feature+Article/Big-Deals/ArticleStandard/Article/detail/490702?contextCategoryId=43875&ref=25 Many say licensing is the new R&D. We've rounded up the unions to watch from the third quarter of 2007. 2008-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072008/490702/Deals_flash.jpg XML http://www.pharmexec.com/pharmexec/News+Analysis/GSK-to-Pay-1-Billion-for-Synta-Melanoma-Drug/ArticleStandard/Article/detail/465605?contextCategoryId=43875&ref=25 In a blockbuster codevelopment deal, GlaxoSmithKline gains rights to an innovative Phase III melanoma drug. 2007-10-17T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/422007/465605null HTML http://www.pharmexec.com/pharmexec/Articles/MampA-Panning-for-Gold/ArticleStandard/Article/detail/455786?contextCategoryId=43875&ref=25 here's a solid case to be made for choosing A. The market for deals has been robust through the first half of 2007. A Cowen research report counted 10 public deals done by July 2007, compared with 14 for all of 2006. Another data source, Irving Levin Associates, cites 455 public and private healthcare deals in the first six months of 2007, a 12 percent decrease from the same period last year—but an 18 percent rise in deal value. 2007-09-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/372007/455786null XML http://www.pharmexec.com/pharmexec/Deals/Novartis-to-Intercell-Gimme-All-Your-Vax/ArticleStandard/Article/detail/440687?contextCategoryId=43875&ref=25 But is the pharma-biotech vaccine deal a prelude to a takeover? 2007-07-11T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282007/440687null HTML http://www.pharmexec.com/pharmexec/Deals/Roche-to-Ventana-Lets-Make-A-Deal/ArticleStandard/Article/detail/440690?contextCategoryId=43875&ref=25 ...And the spurned suitor won't take "No" for an answer 2007-07-11T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/282007/440690null HTML http://www.pharmexec.com/pharmexec/Deals/Actavis-Going-Private/ArticleStandard/Article/detail/442279?contextCategoryId=43875&ref=25 The month in deals: Merck KGaA's generics unit goes to Mylan; Genzyme acquires its partner in a key oncology drug; and Amgen makes significant acquisitions in kidney disease and diabetes/inflammatory diseases 2007-07-03T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/292007/442279null XML http://www.pharmexec.com/pharmexec/Strategy/A-Very-Specialty-Moment/ArticleStandard/Article/detail/429164?contextCategoryId=43875&ref=25 While the most sought-after opinion leaders are often older, well-established physicians, companies should also be aware of the rising stars. Younger, up-and-coming specialists who are beginning to publish are often more cutting-edge and open to experimental approaches. 2007-06-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/212007/429164null XML http://www.pharmexec.com/pharmexec/Deals/Biotech-The-Incredible-Swelling-Industry/ArticleStandard/Article/detail/422950?contextCategoryId=43875&ref=25 New report names 2006 'year of the deal.' 2007-05-02T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/172007/422950null HTML http://www.pharmexec.com/pharmexec/Deals+News/AstraZeneca-Serious-Not-Desperate-in-MedImmune-Dea/ArticleStandard/Article/detail/422933?contextCategoryId=43875&ref=25 Pricey merger adds expertise in vaccines, biologics. 2007-05-02T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/172007/422933null HTML http://www.pharmexec.com/pharmexec/Special+Reports/Spend-Trends-2007-Hang-10/ArticleStandard/Article/detail/423215?contextCategoryId=43875&ref=25 Direct-to-consumer advertising officially becomes a "tweenager" this August—and, oh my, how it has grown. DTC was officially born in 1997 when FDA gave the green light to companies to advertise their drugs to consumers. In the first year, pharmaceutical marketers bounded onto the scene and spent more than $1 billion. Years passed. Debates ensued. Patients learned more about drugs. And, yes, spending grew. The latest available figures for 2006 show that the industry spent $4.8 billion on DTC advertising, a 13 percent increase over 2005 and the second year of double-digit growth. 2007-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/182007/423215null XML http://www.pharmexec.com/pharmexec/Deals+Articles/Deals-Roche-Goes-Shopping/ArticleStandard/Article/detail/423197?contextCategoryId=43875&ref=25 Back in 2003, Roche resolved a long-standing lawsuit with Igen International by acquiring the company. As part of the deal, Roche acquired a perpetual license to use the Igen technology that gave rise to the lawsuit—electrochemiluminescence (ECL)—in certain applications. Igen's ECL patents, meanwhile, were assigned to a new publicly held spin-off company focusing on biosecurity testing, clinical point-of-care products, and vaccines. In March, Roche announced that it was acquiring the spin-off, Maryland-based BioVeris, for $21.50 per share, or a total of about $600 million. 2007-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/182007/423197null XML http://www.pharmexec.com/pharmexec/Deals+Articles/Finance-QampA-with-Annette-Grimaldi/ArticleStandard/Article/detail/408471?contextCategoryId=43875&ref=25 The latest dealmaking trends: Early-stage is back in favor. There's more money to be made in being acquired than in going public. And license deals are putting more on the back end. 2007-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/092007/408471null XML http://www.pharmexec.com/pharmexec/Columns/Pharm-Exec-QampA-Japanese-Wedding/ArticleStandard/Article/detail/322956?contextCategoryId=43875&ref=25 Just how traditional marriages join a couple together from a common culture, Daiichi and Sankyo are merging based on a sense of having come from the same place, and facing the same future. But the art of integration lies in creating new ways of working that make the marriage bigger than the sum of its parts. Officiating the marriage is John Alexander, MD, head of pharma development for Daiichi Sankyo. 2006-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/182006/322956/TN_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Deals+Articles/Deal-Making-Whos-Coming-to-the-Table/ArticleStandard/Article/detail/314753?contextCategoryId=43875&ref=25 Acquired: Intellectual property and technologies related to RNAi, therapeutics for respiratory diseases From: Galenea, Cambridge, MA By: Nastech Pharmaceutical Company, Bothell, WA Terms: Not disclosed 2006-04-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/122006/314753/PE0406_CVR_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Columns/Finance-Promotional-Productivity/ArticleStandard/Article/detail/310971?contextCategoryId=43875&ref=25 Lovenox still needs a defense strategy to hold share, but it requires less investment as a specialty product. Instead, Lovenox should throw cash over to Acomplia, the putative future star of the Sanofi-Aventis portfolio. 2006-03-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/102006/310971/PE_MarCVR_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Biopartnerships/Seven-Principles-for-Fostering-Partnerships/ArticleStandard/Article/detail/197776?contextCategoryId=43875&ref=25 The backbone of the business development process is a series of decision gates with agreed upon decision criteria, and clear expectations for the appropriate levels of research and analysis for each stage in the process. 2005-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/472005/197776/PESupp_cv_tn_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Biopartnerships/Its-All-Academic-Biotechs-Looking-to-Universities/ArticleStandard/Article/detail/197778?contextCategoryId=43875&ref=25 Academic institutions look for a strong committment from the company's senior management, favorable deal terms, market depth in a specific therapeutic area, and alignment with the partner's core strategy. 2005-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/472005/197778/PESupp_cv_tn_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Biopartnerships/Successful-Alliances-Novartis-and-Idenix-Share-the/ArticleStandard/Article/detail/197775?contextCategoryId=43875&ref=25 When it comes to infectious diseases, biotech start-up Idenix is on a mission: to provide patients with treatments that are more effective, more tolerable, and safer than current standards of care. Though small, the Cambridge, Massachusetts-based company is well poised to become a leader in the global antiretroviral market: It has experienced top management, a strong background in medicinal chemistry and drug discovery, and a pipeline of novel treatments for hepatitis B and C and HIV. Until a couple years ago, all Idenix lacked was a financial backer to help pay the way. 2005-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/472005/197775/PESupp_cv_tn_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Biopartnerships/Introduction-Learning-Lessons-and-Looking-Ahead/ArticleStandard/Article/detail/257111?contextCategoryId=43875&ref=25 There's more than one way to slice and dice a deal to understand how value is distributed. In doing so, companies may be better able to construct biopartnerships that not only capitalize on the promise offered by a compound today, but minimize them against losses if a drug doesn't succeed through the pipeline. 2005-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/502005/257111/PESupp_cv_tn_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Biopartnerships/Considering-Intangibles/ArticleStandard/Article/detail/197774?contextCategoryId=43875&ref=25 In order to make the deal work, Argos had to spend a lot of time building the relationship. Taking the time to get to know and trust one another was a key component of Kirin's due diligence process. 2005-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/472005/197774/PESupp_cv_tn_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Biopartnerships/An-11-Step-Program-to-Navigating-Partnerships/ArticleStandard/Article/detail/197777?contextCategoryId=43875&ref=25 In some cases simply contemplating a potential partnership will lead a company to reconsider some of its basic business strategies. That's fine, as long as everyone is clear on one thing: The important goal isn't to make a partnership. The important goal is to advance the business. 2005-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/472005/197777/PESupp_cv_tn_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Biopartnerships/Risks-and-Rewards-How-to-Protect-the-Hand-Youre-De/ArticleStandard/Article/detail/197779?contextCategoryId=43875&ref=25 Poker has become one on the most popular attractions on television and the Internet, right up there with online auctions. And if the two were ever combined—so that players could auction off their hand early in a game, with several rounds of cards remaining to be dealt—bidders might seek advice from folks in pharmaceutical business development. Because that's what we do. When we buy or sell the rights to a compound in development, we are putting a price on a gamble. 2005-10-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/472005/197779/PESupp_cv_tn_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Profiles/Weathering-the-Storm/ArticleStandard/Article/detail/175699?contextCategoryId=43875&ref=25 BMS' use of investigational toxicology puts it in good stead with FDA, which, under its Critical Path initiative, is pushing for more complete toxicology packages. 2005-08-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/342005/175699/TN_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Current+Issue/Sales-Management-Pay-for-Performance/ArticleStandard/Article/detail/170716?contextCategoryId=43875&ref=25 After the merger, Wyeth had dozens of incentive plans for several thousand employees. 2005-07-01T04:00:00Z XML http://www.pharmexec.com/pharmexec/Current+Issue/Legal-Forum-Loss-Causation/ArticleStandard/Article/detail/170705?contextCategoryId=43875&ref=25 Plantiffs did not try to establish a link between the purported misconduct and the decline in share price. Rather, their sole allegation was that they had paid artificially inflated prices for Dura securities. 2005-07-01T04:00:00Z XML http://www.pharmexec.com/pharmexec/PE+Features/Eisais-New-Leadership/ArticleStandard/Article/detail/162034?contextCategoryId=43875&ref=25 I realized that, as president of a pharmaceutical company, I am now a representative of the entire industry. As such, my toughest challenge is listening to and seeing the kind of scrutiny our industry is taking. 2005-05-01T04:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/212005/162034/TN_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/DELETE/Thought-Leaders-Playing-field-in-biotechpharma-par/ArticleStandard/Article/detail/162029?contextCategoryId=43875&ref=25 In the last four or five years—starting in 2000—biotech companies have been able to fund themselves better and are able to do more late-stage development. As biotech companies look toward the future, they do not just want to be research boutiques for the pharmaceutical industry. As a result, pharma companies are accepting the trend towards co-development partnerships for new drugs. 2005-05-01T04:00:00Z XML http://www.pharmexec.com/pharmexec/PE+Features/Patent-Attack/ArticleStandard/Article/detail/161833?contextCategoryId=43875&ref=25 Contrary to myth, Paragraph IV certifications are not reserved only for blockbusters or high-volume primary care products. Three products under recent Paragraph IV challenges had sales of less than $50 million. 2005-04-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/212005/161833/TN_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Current+Issue/Bridging-the-Gap/ArticleStandard/Article/detail/146997?contextCategoryId=43875&ref=25 An effective, high-performing alliance can generate a stronger bottom line outcome. 2005-02-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/082005/146997/thumb_thumbnail.jpg XML http://www.pharmexec.com/pharmexec/Current+Issue/Small-Pharmas-big-Win/ArticleStandard/Article/detail/146992?contextCategoryId=43875&ref=25 The High Court ruled that Abbott should pay the agreed-on royalty of 5 percent rather than the 2 percent it's been paying. The difference may be worth $392 million 2005-02-01T05:00:00Z XML http://www.pharmexec.com/pharmexec/PE+Features/In-Sales-We-Trust/ArticleStandard/Article/detail/146596?contextCategoryId=43875&ref=25 The average salary for all levels of pharmaceutical reps is $62,400 with another $19,300 in cash bonuses, up from a base salary of $53,800 in 2001. 2005-01-01T05:00:00Z http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072005/146596/thumb_thumbnail.jpg http://www.pharmexec.com/pharmexec/data/articlestandard/pharmexec/072005/146596/main_main.jpg XML